开能健康(300272) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was CNY 200,922,590.35, representing a 3.26% increase compared to CNY 194,571,331.74 in the same period last year[7]. - Net profit attributable to shareholders decreased by 91.90% to CNY 868,225.96 from CNY 10,719,512.96 year-on-year[7]. - Net profit excluding non-recurring items fell by 82.51% to CNY 1,717,238.15 compared to CNY 9,816,497.26 in the previous year[7]. - Basic and diluted earnings per share dropped by 91.85% to CNY 0.0015 from CNY 0.0184 year-on-year[7]. - The company's core business revenue from terminal services reached 141.10 million CNY, up 23.19% year-on-year[22]. - Revenue from intelligent manufacturing and core components was 53.81 million CNY, down 22.20% year-on-year[22]. - The company's terminal sales business maintained good growth, leading to a high growth rate in terminal business and service revenue despite a decline in smart manufacturing and core components due to COVID-19 impact[23]. - The total comprehensive income attributable to the parent company is CNY 1,676,654.43, down from CNY 10,596,740.83, a decrease of approximately 84.2%[57]. Cash Flow and Assets - Operating cash flow turned negative at CNY -9,012,489.60, a decline of 139.24% from CNY 22,970,088.63 in the same period last year[7]. - Cash flow from operating activities decreased by approximately 31.98 million CNY, a decline of 139.24% year-on-year, primarily due to increased costs amid the pandemic[21]. - Cash and cash equivalents decreased to CNY 159,789,181.38 from CNY 206,068,322.65, a reduction of about 22.4%[43]. - The company's current assets decreased to CNY 710,956,142.24 from CNY 730,472,914.68, reflecting a decline of approximately 2.1%[43]. - Total assets at the end of the reporting period were CNY 1,952,951,276.20, down 1.00% from CNY 1,972,725,832.32 at the end of the previous year[7]. - Total liabilities decreased to CNY 722,536,216.06 from CNY 743,383,371.42, a reduction of approximately 2.8%[45]. - The company's long-term equity investments remained stable at CNY 103,303,204.96 compared to CNY 103,995,585.96[44]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 18,747[11]. - The largest shareholder, Qu Jianguo, held 37.86% of the shares, amounting to 220,638,209 shares, with 165,478,657 shares pledged[11]. - As of April 13, 2020, the actual controller of the company changed to Mr. Qu Jianguo, who holds 172,456,803 shares, accounting for 29.59% of the total share capital[26]. - Mr. Qu Jianguo directly holds 220,638,209 shares, representing 37.86% of the total share capital, while he has waived voting rights on 40,881,600 shares[26]. - The company reported that 1,026,445 shares held by the controlling shareholder were frozen due to legal proceedings, accounting for 2.19% of the shares held by the shareholder and 0.18% of the total share capital[28]. Research and Development - R&D expenses increased by approximately 3.01 million CNY, a growth of 106.82% year-on-year, due to ongoing new product development[20]. - Research and development expenses for Q1 2020 were CNY 5,821,025.83, up from CNY 2,814,546.49 in the previous period, indicating increased investment in innovation[52]. - Research and development expenses increased to CNY 3,709,000.16 from CNY 1,780,563.89, reflecting a growth of approximately 108.7%[56]. Corporate Governance and Compliance - The company has not reported any significant changes in its intangible assets, core competitiveness, or key technical personnel during the reporting period[23]. - The company is focused on maintaining stable development and governance following the change in control[29]. - The commitment to maintain compliance with legal regulations and company policies regarding related party transactions has been confirmed[33]. - The company has ensured that any necessary related party transactions will be conducted at fair and reasonable commercial terms[33]. - The commitment to avoid conflicts of interest and protect the interests of minority shareholders has been emphasized[33]. Market and Operational Strategy - The company plans to continue focusing on strategic development and has resumed full operations since March 2020[22]. - From March onwards, the company actively resumed production and captured market recovery opportunities, resulting in significant month-on-month growth in core business performance[23]. - The company has established a commitment to avoid competition with Kaineng Environmental, ensuring no direct or indirect competition will occur[33].